93 related articles for article (PubMed ID: 24453570)
1. Costs Associated with Intravenous Cancer Therapy Administration in Patients with Metastatic Soft Tissue Sarcoma in a US Population.
Duh MS; Hackshaw MD; Ivanova JI; Kruse G; Miller LA; Lefebvre P; Karner P; Wong B
Sarcoma; 2013; 2013():947413. PubMed ID: 24453570
[TBL] [Abstract][Full Text] [Related]
2. Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population.
Kruse GB; Amonkar MM; Smith G; Skonieczny DC; Stavrakas S
J Manag Care Pharm; 2008; 14(9):844-57. PubMed ID: 19006441
[TBL] [Abstract][Full Text] [Related]
3. Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis.
Duh MS; Dial E; Choueiri TK; Fournier AA; Antras L; Rodermund D; Neary MP; Oh WK
Curr Med Res Opin; 2009 Aug; 25(8):2081-90. PubMed ID: 19586325
[TBL] [Abstract][Full Text] [Related]
4. Administration costs of intravenous chemotherapy in treating peripheral T-cell lymphoma.
Kruse GB; Potashman MH; Stavrakas S; Wong BJ
J Med Econ; 2014 Jul; 17(7):446-58. PubMed ID: 24758228
[TBL] [Abstract][Full Text] [Related]
5. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
[TBL] [Abstract][Full Text] [Related]
6. Cost of home vs clinic administration of paclitaxel in metastatic breast cancer.
Sharma D; Wojtynek J; Fox KM; Cooper C; Dokubo I
Am J Manag Care; 2021 Feb; 27(2 Spec. No.):SP46-SP50. PubMed ID: 33395244
[TBL] [Abstract][Full Text] [Related]
7. Cost of treatment in patients with metastatic soft tissue sarcoma who respond favourably to chemotherpy. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study.
Jönsson L; Justo N; Musayev A; Krishna A; Burke T; Pellissier J; Judson I; Staddon A; Blay JY
Eur J Cancer Care (Engl); 2016 May; 25(3):466-77. PubMed ID: 25923192
[TBL] [Abstract][Full Text] [Related]
8. Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis.
Duh MS; Reynolds Weiner J; Lefebvre P; Neary M; Skarin AT
Curr Med Res Opin; 2008 Apr; 24(4):967-74. PubMed ID: 18282373
[TBL] [Abstract][Full Text] [Related]
9. The economic burden of metastatic breast cancer: a U.S. managed care perspective.
Montero AJ; Eapen S; Gorin B; Adler P
Breast Cancer Res Treat; 2012 Jul; 134(2):815-22. PubMed ID: 22684273
[TBL] [Abstract][Full Text] [Related]
10. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.
Hao Y; Li N; Fang AP; Koo V; Peeples M; Kageleiry A; Wu EQ; Guérin A
Adv Ther; 2016 Jun; 33(6):983-97. PubMed ID: 27216253
[TBL] [Abstract][Full Text] [Related]
11. Resource utilization and costs following hospitalization of patients with chronic heart failure in the US.
Korves C; Eldar-Lissai A; McHale J; Lafeuille MH; Hwa Ong S; Sheng Duh M
J Med Econ; 2012; 15(5):925-37. PubMed ID: 22502902
[TBL] [Abstract][Full Text] [Related]
12. Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis.
Li N; Hao Y; Koo V; Fang A; Peeples M; Kageleiry A; Wu EQ; Guérin A
J Med Econ; 2016; 19(4):414-23. PubMed ID: 27032967
[TBL] [Abstract][Full Text] [Related]
13. Real-world costs and outcomes in metastatic renal cell carcinoma patients treated with targeted therapies: a cohort study from the French health insurance database.
Maroun R; Fleury L; Nachbaur G; Maunoury F; Vanhille JL; Durand-Zaleski I
Curr Med Res Opin; 2017 Oct; 33(10):1755-1762. PubMed ID: 28748721
[TBL] [Abstract][Full Text] [Related]
14. Real-world Direct Health Care Costs for Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab-containing Regimens in First-line or First-line Through Second-line Therapy.
Johnston S; Wilson K; Varker H; Malangone-Monaco E; Juneau P; Riehle E; Satram-Hoang S; Sommer N; Ogale S
Clin Colorectal Cancer; 2017 Dec; 16(4):386-396.e1. PubMed ID: 28619608
[TBL] [Abstract][Full Text] [Related]
15. Costs, resource utilization, and treatment patterns for patients with metastatic melanoma in a commercially insured setting.
Toy EL; Vekeman F; Lewis MC; Oglesby AK; Duh MS
Curr Med Res Opin; 2015 Aug; 31(8):1561-72. PubMed ID: 26086578
[TBL] [Abstract][Full Text] [Related]
16. Healthcare costs, treatment patterns, and resource utilization among pancreatic cancer patients in a managed care population.
DaCosta Byfield S; Nash Smyth E; Mytelka D; Bowman L; Teitelbaum A
J Med Econ; 2013 Dec; 16(12):1379-86. PubMed ID: 24074258
[TBL] [Abstract][Full Text] [Related]
17. Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: results from a medical chart review study.
Choueiri TK; McDermott D; Sheng Duh M; Sarda SP; Neary MP; Oh WK
Urol Oncol; 2012; 30(6):848-55. PubMed ID: 20926319
[TBL] [Abstract][Full Text] [Related]
18. Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors.
Lin HM; Pan X; Hou P; Huang H; Wu Y; Ren K; Jahanzeb M
J Med Econ; 2020 Aug; 23(8):894-901. PubMed ID: 32347754
[No Abstract] [Full Text] [Related]
19. Survival Rates and Health Care Costs for Patients With Advanced Bladder Cancer Treated and Untreated With Chemotherapy.
Flannery K; Cao X; He J; Zhong Y; Shah AY; Kamat AM
Clin Genitourin Cancer; 2018 Aug; 16(4):e909-e917. PubMed ID: 29735397
[TBL] [Abstract][Full Text] [Related]
20. Analysis of drug and administrative costs allowed by U.S. Private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis.
Wong BJ; Cifaldi MA; Roy S; Skonieczny DC; Stavrakas S
J Manag Care Pharm; 2011 May; 17(4):313-20. PubMed ID: 21534642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
